Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma-Reference-Cited by-同舟云学术

Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma

Published:2013-10-23 Issue:12 Volume:104 Page:1656-1661
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Song Moo-Kon¹,Chung Joo-Seop¹,Lee Je-Jung²,Jeong Shin Young³,Lee Sang-Min⁴,Hong Jun-Shik⁵,Chong Ari⁶,Moon Joon-Ho⁷,Kim Ji-Hyun⁸,Lee Seok-Mo⁹,Kim Seong Jang¹⁰,Shin Ho-Jin¹

Affiliation:

1. Department of Hematology-Oncology; Pusan National University Hospital Medical Research Institute; Busan Korea

2. Department of Hematology; Chonnam National University Hwasun Hospital; Hwasun Korea

3. Department of Nuclear Medicine; Kyungpook National University Hospital; Daegu Korea

4. Department of Hematology; Busan Paik Hospital; Busan Korea

5. Department of Hematology; Gachon University Gil Medical Center; Incheon Korea

6. Department of Nuclear Medicine; Chonnam National University Hospital; Gwangju Korea

7. Department of Hematology; Kyungpook National University Hospital; Daegu Korea

8. Department of Nuclear Medicine; Gachon University Gil Medical Center; Incheon Korea

9. Department of Nuclear Medicine; Busan Paik Hospital; Busan Korea

10. Department of Nuclear Medicine; Pusan National University Hospital; Busan Korea

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.12282/fullpdf

Reference35 articles.

1. Incidence of second cancers in patients treated for Hodgkin's disease;Boivin;J Natl Cancer Inst,1995

2. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood;Leeuwen;J Clin Oncol,2000

3. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger;Ng;J Clin Oncol,2002

4. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials;Franklin;Ann Oncol,2006

5. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials;Noordijk;J Clin Oncol,2006

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Value of Baseline Tumor Burden and Tumor Dissemination Extracted From 18F-FDG PET/CT in a Cohort of Adult Patients With Early or Advanced Hodgkin Lymphoma;Clinical Nuclear Medicine;2023-11-24

2. Pet-radiomics in lymphoma and multiple myeloma: update of current literature;Clinical and Translational Imaging;2023-11-13

3. Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma;Blood Advances;2023-11-02

4. Significance of E-lesions in Hodgkin lymphoma and the creation of a new consensus definition: a report from SEARCH;Blood Advances;2023-10-13

5. Impact of baseline and interim quantitative PET parameters on outcomes of classical Hodgkin Lymphoma;Annals of Hematology;2023-10-05